We can’t show the full text here under this license. Use the link below to read it at the source.
Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
Body composition changes during weight loss with tirzepatide in adults with obesity or overweight
AI simplified
Abstract
Tirzepatide treatment resulted in a 21.3% reduction in body weight after 72 weeks in participants with obesity or overweight.
- Participants treated with tirzepatide experienced a reduction of 33.9% compared to an 8.2% reduction in the placebo group.
- decreased by 10.9% in the tirzepatide group, while the placebo group saw a 2.6% reduction.
- Approximately 75% of the weight lost with tirzepatide was due to fat mass, with 25% attributed to lean mass.
- The proportions of weight loss as fat or lean mass remained consistent across various clinically relevant subgroups.
AI simplified
Key numbers
-21.3%
Body Weight Reduction
Change in body weight from baseline to Week 72 with tirzepatide.
-33.9%
Reduction
Mean percent change in at Week 72 with tirzepatide.
-10.9%
Reduction
Mean percent change in at Week 72 with tirzepatide.